February 2017
J8670 replaces Q9981 when billing Varubi™ (rolapitant)
The Centers for Medicare & Medicaid Services (CMS) has established a permanent procedure code for Varubi™ (rolapitant), effective Jan. 1, 2017.
All services from July 1, 2016, through Dec. 31, 2016, will continue to be reported with code Q9981. All services performed on and after Jan. 1, 2017, must be reported with J8670.
Varubi™ (rolapitant) oral continues to be covered for the approved indications as establisted on July 1, 2016, for the oral antiemetic agent used to prevent delayed chemotherapy-induced nausea and vomiting in patients receiving chemotherapy.
Pharmacy doesn’t require preauthorization of this drug.
|